After more than fourteen years at Emory, Dr. Frank A. Anania, R. Bruce Logue Chair and Digestive Diseases Division Director, will be leaving Emory to join the US Food and Drug Administration. In this role, he will be responsible for building a liver division with a particular focus on non-alcoholic steatohepatitis and liver fibrosis.
During his time at Emory, Dr. Anania rose through the ranks to Professor of Medicine with tenure. As the Department of Medicine’s Division of Digestive Diseases Director, he and his division spearheaded many nationally and internationally-recognized initiatives, including building one of the largest liver transplant programs in the world. In addition, he led the creation of a new GI endoscopy lab at Grady Memorial Hospital and the Atlanta VA Medical Center, and established a top-tier GI fellowship with two advanced programs in the Emory School of Medicine.
Prior to joining Emory, Dr. Anania was a faculty member at both Johns Hopkins University and the University of Maryland Schools of Medicine. His role as a hepatologist in both institutions included clinician, teacher, and biomedical researcher. He actively cared for patients with liver disease in both institutions’ practice plans. Dr. Anania’s clinical work included treatment of complications of chronic liver disease, use of drugs for chronic HCV infection, and a multi-disciplinary approach to patients with NAFLD. He has also cared for patients before and after liver transplantation. His work as a liver investigator was recognized nationally and internationally for discoveries he made that demonstrate the role of adipocytokines in driving liver fibrosis, and for his seminal work on glucagon-like peptide 1 which is now in advanced clinical trials for the treatment of non-alcoholic fatty liver disease.
Please join us in celebrating Dr. Anania’s contributions to his field, Emory University, and the Department of Medicine. We wish him the best in his new role and we look forward to his continued success.